EFTA Document EFTA01447777

look at the up and down history of gene therapy and RNA interference drugs to see the roller coaster likely ahead as researchers try to figure out how to use CRISPR-Cas9 for therapeutics. While Bosley acknowledges the challenges to come, she notes that part of the excitement surrounding CRISPR-Cas9 is that it's come at a time when "our knowledge of the genome is just at a fundamentally different place" than it was many years ago She adds that a lot of progress has been made to combat potent